NASDAQ: TVTXTravere Therapeutics Inc Stock
$60.21-0.68 (-1.12%)
Updated Aug 11, 2026
TVTX Price
$60.21
Fair Value Price
N/A
Market Cap
$5.68B
52 Week Low
$17.05
52 Week High
$66.24
P/E
-133.8x
P/B
231.44x
P/S
8.98x
PEG
N/A
Dividend Yield
N/A
Revenue
$591.33M
Earnings
-$43.46M
Gross Margin
98.6%
Operating Margin
-5.64%
Profit Margin
-7.4%
Debt to Equity
31.6
Operating Cash Flow
$93M
Beta
1.17
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
TVTX Overview
Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. In April 2026, the FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only FDA-approved medicine for FSGS. The company also markets Thiola and Thiola EC (tiopronin tablets) for cystinuria, a rare genetic disorder causing recurring kidney stones. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU). Formerly Retrophin, Inc. (renamed November 2020), Travere is headquartered in San Diego, California, and incorporated in Delaware.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine TVTX's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
TVTX
Ranked#71 of 465
Ranked#71 of 465
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.77 | A | |
| $10.95 | A | |
| $111.86 | A |
Be the first to know about important TVTX news, forecast changes, insider trades & much more!
TVTX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TVTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TVTX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
TVTX is poor value based on its book value relative to its share price (231.44x), compared to the US Biotechnology industry average (5.82x)
P/B vs Industry Valuation
TVTX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more TVTX due diligence checks available for Premium users.
Valuation
TVTX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-133.8x
Industry
16.08x
Market
12.31x
TVTX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
231.44x
Industry
5.82x
TVTX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TVTX's financial health
Profit margin
Revenue
$169.6M
Net Income
-$34.8M
Profit Margin
-20.5%
TVTX's Earnings (EBIT) of -$33.38M... subscribe to Premium to read more.
Interest Coverage Financials
TVTX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$799.4M
Liabilities
$774.8M
Debt to equity
31.6
TVTX's short-term assets ($615.14M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TVTX's long-term liabilities ($622.81M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TVTX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
TVTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$58.1M
Investing
-$206.3M
Financing
$187.5M
TVTX's operating cash flow ($92.70M)... subscribe to Premium to read more.
Debt Coverage Financials
TVTX vs Biotech Stocks
Travere Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.